Progress in nonviral gene therapy for breast cancer and what comes next?
The possibility of correcting defective genes and modulating gene expression through gene therapy has emerged as a promising treatment strategy for breast cancer. Furthermore, the relevance of tumor immune microenvironment in supporting the oncogenic process has paved the way for novel immunomodulatory applications of gene therapy. Areas covered: In this review, the authors describe the most relevant delivery systems, focusing on nonviral vectors, along with the description of the major approaches used to modify target cells, including gene transfer, RNA interference (RNAi), and epigenetic regulation. Furthermore, they highlight innovative therapeutic strategies and the application of gene therapy in clinical trials for breast cancer. Expert opinion: Gene therapy has the potential to impact breast cancer research. Further efforts are required to increase the clinical application of RNAi-based therapeutics, especially in combination with conventional treatments. Innovative strategies, including genome editing and stem cell-based systems, may contribute to translate gene therapy into clinical practice. Immune-based approaches have emerged as an attractive therapeutic opportunity for selected breast cancer patients. However, several challenges need to be addressed before considering gene therapy as an actual option for the treatment of breast cancer.
a Oncology Experimental Therapeutics , IRCCS Clinical and Research Institute Humanitas , Rozzano ( Milan ), Italy.
Giulia
G
Bottai
b Laboratory of Nanomedicine , Department of Biomedical and Clinical Sciences University of Milan, "Luigi Sacco" Hospital , Milano , Italy.
Marta
M
Truffi
c Laboratory of Nanomedicine, Surgery Division , Department of Biomedical and Clinical Sciences University of Milan, "Luigi Sacco" Hospital , Milan , Italy.
Fabio
F
Corsi
a Oncology Experimental Therapeutics , IRCCS Clinical and Research Institute Humanitas , Rozzano ( Milan ), Italy.
Libero
L
Santarpia
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D063646:Carcinogenesis / Q000235:genetics / Q000276:immunology; D002986:Clinical Trials as Topic / Q000379:methods; D044127:Epigenesis, Genetic / Q000235:genetics / Q000276:immunology; D005260:Female; D015316:Genetic Therapy / Q000379:methods / Q000639:trends*; D006801:Humans; D009857:Oncogenes / Q000235:genetics / Q000276:immunology; D034622:RNA Interference / Q000502:physiology; D059016:Tumor Microenvironment / Q000235:genetics / Q000276:immunology
Breast cancer; clinical trials; gene therapy; immunotherapy; nonviral nanovectors; vaccine